NSC 617145 is an inhibitor of WRN helicase activity in vitro with an IC50 of 230 nM and also suppresses WRN ATPase activity in a dose-dependent manner.

BRD-6929 is an inhibitor of histone deacetylase 1 (HDAC1) and HDAC2 with an IC50s of 0.04 µM and 0.1 µM, respectively. It exhibits antiproliferative activities against a human cancer cell line (HCT116) and in human mammary epithelial cells (HMEC).

LDN-27219 is a potent, reversible, slow-binding inhibitor of Tissue transglutaminase (TGase), which exhibits IC50 of 0.6 μM against human hTGase. It likely binds at the GTP-binding or regulatory site rather than the enzyme’s active site. It lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries in an age-dependent manner.

LDN-27219 is a potent, reversible, slow-binding inhibitor of Tissue transglutaminase (TGase), which exhibits IC50 of 0.6 μM against human hTGase. It likely binds at the GTP-binding or regulatory site rather than the enzyme’s active site. It lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries in an age-dependent manner.

Soticlestat (TAK-935, OV935) is a potent, selective, and orally active inhibitor of Cholesterol 24-hydroxylase (CH24H). It may have therapeutic potential for diseases associated with neural hyperexcitation and severe epilepsy syndrome.

Ivarmacitinib (SHR0302) is a potent and orally active inhibitor of JAK family, particularly JAK1. Ivarmacitinib demonstrates more than 10-fold selectivity for JAK1 over JAK2, 77-fold over JAK3, and 420-fold over Tyk2. Ivarmacitinib also exhibits anti-proliferative and anti-inflammatory effects.

Soticlestat (TAK-935, OV935) is a potent, selective, and orally active inhibitor of Cholesterol 24-hydroxylase (CH24H). It may have therapeutic potential for diseases associated with neural hyperexcitation and severe epilepsy syndrome.

Ivarmacitinib (SHR0302) is a potent and orally active inhibitor of JAK family, particularly JAK1. Ivarmacitinib demonstrates more than 10-fold selectivity for JAK1 over JAK2, 77-fold over JAK3, and 420-fold over Tyk2. Ivarmacitinib also exhibits anti-proliferative and anti-inflammatory effects.

Atuliflapon (AZD5718) is an oral inhibitor of (FLAP) 5-lipoxygenase activating protein with an IC50 of 2.0 nM. It has the potential to treat coronary artery disease.

FSG67 is an inhibitor of glycerol 3-phosphate acyltransferase (GPAT) with an IC50 of 24 μM. It increases oxidative metabolism in mature adipocytes and blunts liver regeneration after acetaminophen overdose by altering GSK3β and Wnt/β-catenin signaling.